3 results about "Radioimmunotherapy" patented technology

This application relates to the field of biomedical technology, specifically disclosing a therapeutic probe targeting neuroblastoma GD2, adapted to the clinical needs of relapsed, refractory, and high-risk neuroblastoma. This therapeutic probe comprises paired diagnostic and therapeutic components, both using the humanized anti-GD2 monoclonal antibody hu3F8 as the sole targeting carrier; the diagnostic component is a zirconium-89-labeled deferoxamine-hu3F8 conjugate, and the therapeutic component is an actinium-225-labeled DOTA-hu3F8 conjugate. This application also discloses its preparation method, obtaining a high-purity product through three steps: antibody-chelating agent conjugation, radionuclide labeling, and purification. This probe system can be used to prepare a therapeutic drug composition for neuroblastoma, exhibiting strong targeting specificity, enabling imaging-guided precise radioimmunotherapy, and demonstrating good synergistic diagnostic and therapeutic effects.

The application discloses a kind of bioactive polyamino acid nanocomposites, preparation method and purposes, by condensation reaction synthesis hyaluronic acid-block-poly amphiphilic block copolymer, by hydrophobic, electrostatic, metal coordination etc. Interaction covers CD73 small molecule inhibitor APCP and PD1 / PD-L1 inhibitor S7911, preparation HA@APCP / S7911.HA@APCP / S7911 is enriched in tumor area by EPR effect, under the joint action of hyaluronidase and low pH in tumor area, realize the release of APCP and S7911 in tumor tissue.APCP is inhibited CD73 enzyme activity, restores the metabolism and activity of NK cell, starts NK cell immune response;S7911 is inhibited after release in tumor tissue PD-L1 and PD-1 binding, blocks immune checkpoint and starts T cell immunity, combined with radiotherapy to improve antitumor immune response, amplify the range of effective immune response, for promoting the combined effect of radioimmunotherapy provides a new way of thinking.

This application relates to the fields of biomedicine and nuclear medicine, specifically disclosing a GD2-targeted therapy probe and its radioimmunotherapy application. It aims to address the limitations of existing probes in simultaneously achieving radionuclide labeling efficiency and antibody targeting activity, and their limited efficacy against relapsed / refractory neuroblastoma and minimal residual disease. This probe uses a hu3F8 antibody as the targeting carrier and Nota and DOTA as chelating agents to respectively match… 64 Cu、 177 Lu, a single antibody molecule coupled with 3-5 chelating agent molecules. This application also discloses a precise preparation method for the probe and its application in GD2-positive tumor PET imaging, radioimmunotherapy, SPECT monitoring, combined immunotherapy, and minimal residual disease clearance. This probe achieves integrated diagnosis and treatment, possessing high activity, high targeting, and low toxicity, showing excellent prospects for clinical translation.